Background
==========

Asbestos is a potent carcinogen and the most important single cause of mesothelioma, a mostly fatal cancer of the pleura \[[@B1]-[@B3]\]. Only about 20% of mesothelioma cases occur in non-exposed individuals \[[@B4],[@B5]\]. Previous studies have shown that mesothelioma mortality rates correlate with past asbestos consumption rates (defined by production minus export plus import) in industrialized countries \[[@B1],[@B6]\]. During the past 40 to 50 years, asbestos consumption varied considerably in European countries, with low *per capita*use in less industrialized countries, such as Bulgaria, and vast use in ship building and other insulating industries,*e.g.*in the U.K. Since the time lag between asbestos exposure and tumor development is 30 to 45 years in most cases, the recent increase in mesothelioma incidence should therefore reflect the intensified use of asbestos during this particular period \[[@B3],[@B7]-[@B9]\]. Indeed, the production of asbestos peaked worldwide in the late 1970s and early 1980s \[[@B10]\]. Likewise, the mesothelioma incidence is expected to reach maximum levels between 2010 and 2020 in industrialized countries \[[@B6]\]. About half of the cases will occur in construction and shipbuilding workers, as in these professions asbestos exposure was particularly common \[[@B6]\]. Incidence is much lower in women, as they were generally, not involved in asbestos-related activities \[[@B11]\].

The fact that traces of simian virus 40 (SV40) were repeatedly demonstrated in a significant proportion of mesothelioma samples led to the notion that this virus may act as either a co-carcinogen or tumor promoter \[[@B12]-[@B14]\]. SV40 was introduced unintentionally into millions of people *via*contaminated poliomyelitis virus vaccines between 1955 and 1963. However, some vaccines produced later may have not been entirely SV40-free, as evidenced by the fact that SV40 DNA has been recently detected in archival polio vaccines produced in 1966 and 1969 by a major Eastern European manufacturer \[[@B15]\]. SV40 was present in both the attenuated (oral) polio vaccine (OPV) and the inactivated polio vaccine (IPV), since formaldehyde treatment, which was used to inactivate the poliomyelitis virus, failed to inactivate SV40 \[[@B12]\].

SV40 DNA was subsequently detected in human brain and bone tumors as well as lymphoma samples (reviewed in \[[@B16]\]). Intriguingly, SV40 causes the same tumor types in hamsters \[[@B4]\]. The most important step in the process of carcinogenesis is the inactivation of tumor suppressor p53 and members of the retinoblastoma family of proteins through the SV40 large T antigen \[[@B17]\]. In addition, other tumor suppressor genes become methylated and are shut down. These gene modifications have not only been observed *in vitro*, but also in an analogous fashion in SV40-positive lymphoma samples \[[@B18]\].

However, it is important to note that SV40 DNA was not detected in several studies of tumor samples from particular populations, whereas it was readily detectable in appropriate control samples from the USA \[[@B19],[@B20]\]. In particular, SV40 DNA was not detected in mesothelioma, brain tumor and bone tumor samples from Austria, Finland and Turkey, countries which apparently had never used contaminated polio vaccines \[[@B19]-[@B24]\]. These findings were therefore taken as evidence that the population-specific and linked geographic differences were genuine and that they reflected the heterogeneous use of SV40-contaminated polio vaccines in the respective countries \[[@B4]\]. However, definitive epidemiological proof for the presence or absence of an association between (past) SV40 exposure and cancer is lacking so far, mostly because the infected cohorts can no longer be identified unambiguously \[[@B4]\].

The presence of virus-specific antibodies in serum is a well-established biomarker of viral infection. Antibodies to SV40 have been measured in humans by plaque inhibition neutralization assays and enzyme immunoassays. However, the studies have been mostly negative or detected only low levels of SV40 serum antibodies \[[@B25]-[@B28]\]. Cross-reactivity between SV40 and the BK polyomavirus has been proposed as an explanation for the detection of low levels of SV40-reactive antibodies in human serum samples and may complicate the interpretation of positive assay results \[[@B27]\]. In a recent population-based case-control study published by Engels *et al.*\[[@B26]\] using competitive assays to analyze SV40-specific reactivity, it has been shown that an estimate of 1% to 1.6% individuals from the U.S. born before 1963 had SV40 specific antibodies, whereas those born later showed no SV40 specific reactivity. The authors stated that these results point to the possibility that exposure to SV40 could have led to antibody responses that declined over the decades, probably due to lack of virus replication, and that SV40 seems not to be a common cause of infection in humans \[[@B26]\].

However, the past exposure of humans to SV40 is undoubted. We therefore set out to investigate whether mesothelioma (pleural cancer) incidence and mortality rates might be higher in those European countries (including the former Communist countries), in which at least some circumstantial evidence indicates that a population-wide exposure had taken place. For this purpose, we first investigated to what extent pleural cancer mortality rates correlate with those of past asbestos use. We then compared country-specific asbestos consumption and mesothelioma rates with the appropriate likelihood of SV40 contamination. To ascertain whether the respective SV40 exposure was frequent, low or absent in specific countries, we used data from publications that dealt with the analysis of SV40 DNA in human tissue samples. In addition, we also collected all the available information about which type of poliomyelitis virus vaccines had been used in these countries and whether they were SV40-contaminated or not.

Methods
=======

Study design
------------

We conducted a Medline search for the period from January 1969 to August 2005 with use of the following terms and Boolean operators: ((\"SV40\" OR \"simian virus 40\") AND (\"tumor\" OR \"tumour\" OR \"cancer\")) or ((\"SV40\" OR \"simian virus 40\") AND (\" \[country\]\" OR \" \[country language\]\")) or ((\"SV40\" OR \"simian virus 40\") AND (\"Europe\*\")). All abstracts were checked for valid results on SV40 DNA in human tissue samples or for information about past poliomyelitis virus vaccination programs in European countries. The bibliography of each paper was then further screened by two researchers for additional relevant studies.

Inclusion and exclusion criteria for molecular genetic studies
--------------------------------------------------------------

Articles were independently examined in detail by two investigators (A.L. and K.L.). All studies on SV40 in human tissue samples (mostly tumors) or body fluids derived from a European country were considered for analysis. Eligibility criteria: Only original articles on SV40 detection were included. The origin of the samples had to be clearly stated. As an inclusion criterion, SV40 nucleic acid hybridization or polymerase chain reaction (PCR) methods had to be performed for SV40 detection. Studies on cell lines were not included. One study was excluded because the SV40-positive patient was the newborn child of foreign guest workers \[[@B29]\]. In one study from Berlin, the origin of the patients was not clear (Western or Eastern Germany), the study was therefore excluded \[[@B30]\]. One study with data on SV40 DNA in sewage from two European cities was excluded from the analysis \[[@B31]\]. Although SV40 may be shed in stool \[[@B32]\] the implications of these data are unclear since comparable studies are missing. The relevant data from of the eligible studies were abstracted by one researcher and rechecked for accuracy by another. In particular, we extracted the following information: origin of the tissue specimen, tumor or non-tumor tissue, type of tumor, number of SV40-positive samples, number tested, and detection method.

Inclusion and exclusion criteria for reports on SV40 in vaccines
----------------------------------------------------------------

All reports retrievable from the Medline search or from the bibliography of each paper containing data on SV40 contamination of vaccines used in a specific European country were eligible for analysis.

Mesothelioma mortality data
---------------------------

In the absence of a specific International Classification of Diseases \[ICD\] code for mesothelioma until the introduction of a specific code for mesothelioma (C45) in the 10^th^revision of the ICD in 1992 \[[@B33]\], pleural cancer (ICD 163) death rates were used for the analysis. Mortality of pleural cancer is mainly attributed to mesothelioma \[[@B34]\] and corresponds reasonably with mesothelioma incidence, since most patients diagnosed with mesothelioma will die within one year \[[@B3]\]. For each country, age-standardized (world standard population) pleural cancer mortality rates were extracted from the World Health Organization (WHO) database \[[@B35]\]. Mortality data from 1985 to 1989 were used because of the unification or division of some European countries after the end of the Cold War (about 1989), in order to allow correlation with former country-wide asbestos consumption data. To allow comparability, the WHO database \[[@B35]\] was the only source of pleural cancer mortality/incidence data used. Cancer incidence rates are known to have been underestimated until 1992 in Belgium (DeVuyst, Hopital Erasme, Brussels, personal communication and \[[@B36]\]), therefore, in the case of Belgium, pleural cancer mortality from 1995 to 1999 was retrieved from the WHO mortality database \[[@B33]\] and was compared to asbestos consumption in 1970 in Belgium-Luxembourg. Since data from Turkey were not retrievable from the WHO database \[[@B35]\], Turkish mesothelioma incidence in 1996, as reported by Menintas *et al.*\[[@B37]\], was correlated with asbestos consumption in 1970.

Asbestos consumption data
-------------------------

Asbestos consumption data were provided by the U.S. Geological Survey, Reston, VA \[[@B10]\]. For some countries, the information about either asbestos or pleural cancer mortality was unfortunately incomplete: these data were therefore excluded from further analysis.

Statistical analysis
--------------------

For statistical analyses, the NCSS 2001 (NCSS Statistical Systems, Kaysville, UT, USA) software package was used. *P*\< 0.05 was considered to be significant. The Spearman\'s correlation coefficient was calculated for the following variables: male/female pleural cancer mortality and asbestos consumption. ANCOVA was used for group comparisons with past asbestos consumption as a covariate, and male/female pleural cancer mortality as a dependent variable. No adjustment for multiple testing was done.

Results
=======

Mesothelioma and asbestos
-------------------------

When we correlated male pleural cancer death rates in 18 European countries with *per capita*asbestos consumption 25 to 30 years earlier, we found a linear relationship (Figure [1](#F1){ref-type="fig"}). The Spearman\'s correlation coefficient of the two variables is R = 0.603 (*P*= 0.008). Notably, all European countries with available information on asbestos consumption and pleural cancer mortality were included in the analysis (the sources are indicated in the methods section). For females, no linear relationship could be demonstrated (Figure [2](#F2){ref-type="fig"}). The Spearman\'s correlation coefficient of the two variables is R = 0.293 (*P*= 0.239).

![Correlation between *per capita*asbestos consumption and male pleural cancer mortality rates (R = 0.603, *P*= 0.008). In the legend SV40 detection refers to SV40 nucleic acid detection at a cut-off level of 10%. *Per capita*asbestos consumption in a state was calculated as the production plus imports minus exports of all types of asbestos (Data from U.S. Geological Survey).](1750-1172-1-44-1){#F1}

![*Per capita*asbestos consumption and female pleural cancer mortality rates in European countries. In the legend SV40 detection refers to SV40 nucleic acid detection at a cut-off level of 10%.*Per capita*asbestos consumption in a state was calculated as the production plus imports minus exports of all types of asbestos (Data from U.S. Geological Survey).](1750-1172-1-44-2){#F2}

SV40 data
---------

According to our criteria, 55 original articles on SV40 in human tissue samples or body fluids derived from 13 European countries contained information relevant to our analysis (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, Table [1](#T1){ref-type="table"}). For all countries except the U.K., data for pleural cancer mortality and past asbestos use were available. Thus, 12 countries were included in the statistical analysis. The cut off level for SV40 detection was set at 0% or 10% positive tumor samples, respectively (Figure [3](#F3){ref-type="fig"}). Before analyzing the effect of SV40 prevalence, we corrected male pleural cancer rates for asbestos consumption because these two variables are highly correlated. However, whether SV40 DNA had been detected in tumor samples from a particular country or not, had no effect on pleural cancer mortality rates at either cut-off level, neither in males (asbestos-corrected rates) nor in females (Table [2](#T2){ref-type="table"}).

![Frequencies of SV40 nucleic acid detection in European human tissue samples. Only reports using polymerase chain reaction or hybridization techniques were included. The original reports are cited in Table 1. Pleural cancer mortality data were not available for the entire United Kingdom, which was therefore excluded from statistical analysis.](1750-1172-1-44-3){#F3}

![Map of SV40 nucleic acid detection and historical vaccine contamination with SV40 in European countries. For nucleic acid detection a cut-off level of 10% (SV40 positive samples from a country of total examined samples) was chosen.](1750-1172-1-44-4){#F4}

###### 

SV40 nucleic acid detection in human samples

  Country                   *Positive*reports on SV40 nucleic acids   *Negative*reports on SV40 nucleic acids   SV40 detection at 0% cut-off level   SV40 detection at 10% cut-off level
  ------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------ -------------------------------------
  Austria                                                             \[21,22\]                                 \-                                   \-
  Belgium                   \[38,39\]                                 \[40,41\]                                 \+                                   \+
  Finland                                                             \[19,23\]                                 \-                                   \-
  France                    \[42\]                                    \[41,43\]                                 \+                                   \+
  Germany West              \[44-51\]                                 \[52-54\]                                 \+                                   \+
  Germany East              \[55\]                                                                              \+                                   \+
  Hungary                   \[51\]                                                                              \+                                   \+
  Italy                     \[14,17,47,56-70\]^a^                     \[71-73\]                                 \+                                   \+
  Spain                     \[74\] low positive                       \[71,75\]^b^                              \+                                   \-
  Sweden                    \[76\]                                                                              \+                                   \+
  Switzerland               \[77\] data also presented in \[23\]                                                \+                                   \+
  Turkey                                                              \[20,24\]                                 \-                                   \-
  United Kingdom^c^         \[78-81\]                                 \[82-85\]                                 \+                                   \+
                                                                                                                                                     
  Total number of studies   37                                        18                                                                             

Percent cut-off level refers to percentage of SV40-positive human tissue samples in all samples tested in a country.

^a^Healthy subjects were tested in \[70\].

^b^One study \[75\] contained only uterine cervix carcinoma samples.

^c^Pleural cancer mortality data were available only for England and Scotland, but not for the entire U.K., therefore the U.K. was excluded from further statistical analysis.

###### 

Comparison of pleural cancer mortality rates in countries with or without molecular genetic evidence of SV40

  Category   Cut-off level   Mean pleural cancer mortality in SV40-nucleic acid *positive*countries (/100 000/yr)   Mean pleural cancer mortality in SV40-nucleic acid *negative*countries (/100 000/yr)   *P*
  ---------- --------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------
  Males\*    0%              0.97 (n = 9)                                                                           0.81 (n = 3)                                                                           0.465
  Females    0%              0.31 (n = 9)                                                                           0.31 (n = 3)                                                                           0.956
  Males\*    10%             1.04 (n = 8)                                                                           0.69 (n = 4)                                                                           0.082
  Females    10%             0.33 (n = 8)                                                                           0.28 (n = 4)                                                                           0.397

Cut-off level refers to the percentage of SV40-positive human tissue samples of all samples tested in a country. \*Asbestos-corrected rates.

Poliomyelitis virus vaccines
----------------------------

Information regarding the type of poliomyelitis virus vaccine (and whether it had been SV40-contaminated or not) was eligible from 15 countries (Table [3](#T3){ref-type="table"}). In ten countries, the usage of SV40-contaminated polio vaccines is unambiguously documented, while in three other countries SV40-contaminated vaccines had apparently not been used (Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"}). For Spain and Poland, contradictory reports exist (Table [3](#T3){ref-type="table"}). For ten countries with either positive or negative SV40 contamination of vaccines, data on asbestos consumption and pleural cancer were available (see Figure [1](#F1){ref-type="fig"}, sources are indicated in the methods section). Our statistical analyses revealed that whether the polio vaccine was contaminated or not, had no impact whatsoever on male asbestos consumption-corrected or female pleural cancer rates. In males, the mean asbestos-corrected mortality rate was 0.77/100 000 (n = 7) in countries with SV40-contaminated vaccines and 0.83/100 000 (n = 3) in countries without SV40-contaminated vaccines (*P*= 0.700). In females, the mean mortality rate was 0.24/100 000 (n = 7) in countries with SV40-contaminated vaccines and 0.31/100 000 (n = 3) in countries without SV40-contaminated vaccines (*P*= 0.377).

###### 

SV40 in poliomyelitis virus vaccines in European countries

  Country          Rating of contamination of polio vaccines with SV40   Vaccines, vaccination programs and origin of vaccines
  ---------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Albania          Positive                                              Contaminated Russian vaccine (OPV) used since 1960 \[86-90\].
  Austria          Negative                                              Mass vaccinations with SV40-free British vaccine (OPV) since winter 1961/62 \[91-92\].
  Bulgaria         Positive                                              Contaminated Russian vaccine (OPV) used since 1960 \[86-90\].
  CSSR             Positive                                              Since 1960: limited use of IPV, mass vaccinations with OPV, partly with contaminated Russian vaccine \[86-90,93-94\].
  Denmark          Positive                                              Vaccinations from 1955 with widely contaminated Danish vaccine (IPV), SV40-free from 1963 \[95\]. A combined schedule was introduced in 1968 \[96\].
  Finland          Negative                                              Mass vaccinations since 1957 with SV40-free Belgium vaccine (IPV) \[19\]. Finland has never used OPV on a routine basis \[96\].
  Germany East     Positive                                              Contaminated Russian vaccine (OPV) used since 1960 \[55, 87-90, 97\].
  Hungary          Positive                                              Since 1957: limited use of IPV, mass vaccinations with vaccines from the US, Canada, Hungary and Russia (also OPV) \[87-90\].
  Norway           Positive                                              Vaccinations started 1956 with Danish vaccine (IPV); since 1957 potentially contaminated U.S. vaccine (IPV) \[98\], change to OPV from 1967 to 1979, then back to IPV from 1979 onwards \[96\].
  Poland           Unclear                                               Mass vaccinations (OPV) since 1958 with Koprowski strain live vaccine \[94\]; vaccine was claimed to be Russian made \[99\], but Russian vaccines were derived from Sabin\'s strain \[86\].
  Russia (USSR)    Positive                                              Mass vaccinations since 1959 with contaminated Russian vaccine (OPV). A small proportion of persons were vaccinated with IPV at the beginning of the mass vaccinations. \[86-90, 100\].
  Spain            Unclear                                               Mass vaccinations since 1963 with British vaccine (OPV) \[101\]; British vaccines were SV40-free since 1962 \[102\]; in contrast some vaccines were later claimed to have been contaminated \[103\].
  Sweden           Positive                                              In 1957 potentially contaminated U.S. vaccine (IPV), from 1958 SV40-free Swedish vaccine (IPV). Sweden has never used OPV \[96\].
  Turkey           Negative                                              Vaccination was not started before 1970, at a time where polio vaccines were required to be SV40-free \[20, 24\]. The type of the vaccine is unclear. In a global poliomyelitis eradication initiative starting in 1989, OPV was used.
  United Kingdom   Positive                                              Vaccination started in 1956 with OPV \[104-105\]. SV40-free since 1962 \[102\].

CSSR: Czechoslovak Socialist Republic; OPV: oral polio vaccine; IPV: inactivated polio vaccine.

In addition, we analyzed the impact of the type of vaccine (IPV or OPV) used between 1957 and 1963 on pleural cancer rates in Europe. In two of the ten countries (Sweden and Finland), IPV was the only vaccine used at least until 1996, in two other countries (Denmark and Norway) OPV was used as well as IPV, but not before 1967, when Western European vaccines were SV40 free. In four countries, OPV was used between 1957 and 1963, together with variable exposure to IPV. In one country (Hungary) the predominant type of vaccine used between 1957 and 1963 is unclear, and in one country (Turkey) apparently no vaccine has been used between 1957 and 1963. In countries with past use of contaminated IPV, the mean male asbestos-corrected pleural cancer rate was 0.95/100 000 (n = 3), and was 0.77/100 000 (n = 5) in all other countries (*P*= 0.381). In countries with past use of contaminated OPV, the mean male asbestos-corrected pleural cancer rate was 0.77/100 000 (n = 3) and was 0.87/100 000 (n = 5) in all other countries (*P*= 0.619). In countries with past use of contaminated IPV, mean female pleural cancer rate was 0.23/100 000 (n = 3) and was 0.28/100 000 (n = 5) in all other countries (*P*= 0.636). In countries with past use of contaminated OPV, mean female pleural cancer rate was 0.25/100 000 (n = 3) and was 0.27/100 000 (n = 5) in all other countries (*P*= 0.844). Therefore, we did not find any significant differences in pleural cancer rates from countries with past use of SV40-contaminated IPV or OPV compared to the other European countries.

Discussion
==========

The main purpose of this ecological analysis was to explore the potential effect of a country-wide presence of SV40 on the respective pleural cancer mortality rate, presuming that SV40 has the long adjudicated tumor-inducing or -promoting role in humans. A country-wide presence of SV40 was inferred from previous vaccination programs with contaminated vaccines or the detection of virus DNA in tumor samples. Although the results of our analyses confirmed the previous well-established association between the male pleural cancer mortality rate and the extent of the asbestos consumption 25 to 30 years earlier, we failed to detect any discernible effect on the respective male or female pleural cancer mortality rates that could have been allocated to SV40.

The oncogenic potential of SV40 and the mode of its introduction into the human population *via*contaminated vaccines are well documented (for review see \[[@B12]\]). However, whether viral infection indeed also represents a risk factor for tumor development in humans is still a rather controversial issue, which at present is primarily supported by spurious molecular genetic studies, but not by firm epidemiological evidence \[[@B106]\]. However, even the question of whether SV40 is actually present in human tumors and if so, what role it might play in tumor development, is currently unsolved and a matter of ongoing debate, especially since two multi-center studies reached different conclusions \[[@B107],[@B108]\]. Epidemiological studies about tumors developing in recipients of SV40-contaminated vaccines are mainly hampered by the fact that the infected cohorts are difficult to identify, because SV40 has been found in tumors of patients that were too young to have been exposed to contaminated vaccines \[[@B4]\].

To differentiate between SV40-contaminated and SV40-free European countries, we collected all eligible studies dealing with this topic and extracted the relevant information. However, we excluded all studies which had merely used immunological and serological detection procedures, because SV40 and the human BK and JC polyomaviruses are known to cross-react to a high degree \[[@B109]-[@B113]\]. For the same reason, we also excluded reports that dealt with serum antibodies against SV40. We were nevertheless able to identify three countries (Austria, Finland and Turkey), in which exclusively SV40-free polio vaccines had been used. Incidentally, these were the same countries in which molecular genetic studies failed to detect SV40 DNA in a representative large number of tumor samples \[[@B19]-[@B24]\].

Although we were unable to find any epidemiological evidence for a potential association between SV40 and pleural cancer, the following limitations of our analysis have to be taken into consideration. First of all, we were unable to account for different types and particular usage of asbestos. Instead, we used the asbestos data from a single source, the U.S. Geological Survey \[[@B10]\]. Naturally occurring asbestos is found in soils or rocks in certain villages in southeast Turkey, where it causes endemic occurrence of mesothelioma \[[@B114]\], and also in other parts of the world, *e.g.*in California \[[@B115]\]. However, it was not possible to correct for the impact of natural asbestos deposits in the cohorts used in this study. Even if Turkey is excluded from the analysis, no significant association between SV40 and pleural cancer is found, neither in males (asbestos-corrected rates), nor in females (data not shown).

Second, differences in cancer registration exist and increasing diagnostic awareness in the past 20 years may have affected the reported mortality rates. Miscoding might have occurred in countries where only death certificates were used for mesothelioma registration \[[@B34]\]. To optimize comparability, we therefore used the WHO database as our only source of information. In the majority of cases, we used mortality data from 1985 to 1989. More recent mortality rates from the WHO mortality database would not allow comparability of mortality rates with former country-wide asbestos consumption data because of the unification or division of certain European countries after the end of the Cold War (about 1989). Data from the International Agency for Research on Cancer (IARC) database \[[@B116]\] were not suitable, because for many countries the incidence rates are indicated on a district-basis only, and not in a country-based fashion. However, the important limitation of possibly incorrect pleural cancer rates could not be overcome in the current study. Therefore, improvements in cancer registration are important for future studies addressing these questions.

Third, methodological differences in SV40 screening procedures (*e.g.*different PCR primers, frozen versus paraffin embedded tissues) lead to unequal sensitivities \[[@B117]\]. An unknown proportion of positive SV40 DNA results may have been related to contamination or to other problems with the PCR methods \[[@B118]\]. Optimized laboratory procedures for SV40 detection have been only recently defined \[[@B119]\]. However, as is suggested, mostly by the laboratory investigators themselves, there might be a relationship between country-specific PCR results and geographic variations in SV40 occurrence \[[@B4]\] and hence mesothelioma incidence. Therefore, to study geographic variations, we chose to assume the accuracy of the prior positive PCR results. The different sample sizes of the SV40 detection studies were taken into account by assessing the number of samples with positive SV40 nucleic acid detection versus the whole number analyzed samples for each eligible study. Further issues that also have to be considered in such analyses are, of course, that potential but yet undefined specific genetic factors might influence the likelihood of mesothelioma development in different populations \[[@B120]\].

In the United States, a potentially contaminated poliomyelitis virus vaccine was used between 1955 and 1963 nationwide on about 90% of children and 60% of adults \[[@B16],[@B121]\]. In Europe, approximately 60% of the population received a potentially contaminated vaccine \[[@B121]\]. However, the SV40 prevalence in many European countries is more mosaic-like, because it still mirrors the pattern of when and with which vaccine mass vaccination programs were initiated by local governments. At the beginning of our investigation, we were confident that we could obtain the necessary SV40 data from the vaccine producing companies, which would have been the most efficient and accurate way of determining the pattern of use of contaminated vaccines. However, many of our requests remained unanswered and in some instances the relevant information had apparently already been destroyed, unclear statements were frequent. Therefore, national health bulletins (like those issued in Austria and Spain) became a particularly important resource \[[@B91],[@B92],[@B101]\]. Reports on historical SV40 contamination of vaccines may be of varying accuracy, depending on the detection methods used and on the number and source of samples (batches) tested. However, all data were assumed to be of equal weight because weighting of such heterogenous data was not possible. Moreover, other routes of transmission may exist. Epidemiological evidence suggests that SV40 may be contagiously transmitted in humans by horizontal infection, independent of the earlier administration of SV40-contaminated polio vaccines \[[@B113]\]. Recently, even infection through laboratory strains of SV40 has been proposed \[[@B122]\].

Although little is known about the severity of SV40 infection in humans (systemic or non-systemic), some data indicate that there might be biological differences depending on the type of exposure (IPV *vs.*OPV). After oral administration of SV40 in humans, there was no antibody response, indicating that it most likely did not result in systemic infection, which would most likely be necessary for cancer induction (for review see \[[@B88]\]). On the other hand, after subcutaneous inoculation of SV40-contaminated inactivated vaccines, antibody titers were high and remained high or declined slightly over a 3-year follow-up \[[@B88]\]. After 1961, IPV was replaced in many countries by OPV, although a few continued to use IPV and others subsequently reintroduced it. We identified four countries that used only IPV between 1957 and 1963 and recalculated differences in mean pleural cancer rates taking into account the type of vaccine used in the country. However, whether SV40-contaminated OPV or IPV was used in a specific country had no impact on asbestos-corrected (male) or raw (female) pleural cancer rates. Many countries used IPV to a variable extent before mass vaccinations with OPV. Unfortunately, hardly any information about these vaccination programs remains available. Therefore, the level of exposure to IPV could not be exactly determined for every country.

We used two different approaches to analyze the association between SV40 prevalence and pleural cancer mortality in European countries. First, we used data on historical SV40 exposure. However, the infected cohorts are diluted by individuals not vaccinated during the possible time of infection or vaccinated with SV40-free vaccines. Second, we screened the literature for molecular genetic evidence of SV40 in tumor samples from the different countries. The methods applied would detect only a strong carcinogenic or co-carcinogenic effect of SV40 on the pleura (in males aggregated by country) because of the crude adjustments for asbestos consumption, without distinguishing between chrysotile and amphibole asbestos. However, the results of this study, the negative SV40 DNA reports, and the serologic data argue against a major role of SV40 in mesothelioma carcinogenesis.

Conclusion
==========

Finally, despite all the shortcomings and problems, our comprehensive data collection provides the first account of the diverse usage of different types of poliomyelitis virus vaccines from all available data from European countries. In conjunction with the records obtained from the molecular genetic screening for SV40 DNA in tumor samples derived from the respective populations, it provides the best achievable distribution map available to date on SV40 prevalence in Europe and the basis for future reassessments of epidemiological SV40 data, whenever new information becomes available. This ecological analysis makes an association of male pleural cancer with SV40 unlikely, but this needs to be confirmed by case control studies and cohort studies.
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